Education
About Us
Working with TipRanks
Follow Us
Processa Pharmaceuticals (PCSA)
NASDAQ:PCSA
RESEARCH TOOLSreports
PCSA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.15 - $3.10
Previous CloseN/A
Volume113.34K
Average Volume (3M)4.25M
Market Cap
$3.43M
Enterprise ValueN/A
Total Cash (Recent Filing)$1.19M
Total Debt (Recent Filing)$73.51K
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 07, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding11,884,356
10 Day Avg. Volume8,769,426
30 Day Avg. Volume4,247,406
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.00Price Target Upside1968.97% Upside
Rating ConsensusHold
Number of Analyst Covering1
Processa Pharmaceuticals News
PremiumCompany Announcements
Processa Pharmaceuticals Raises $5M in Public Offering
PremiumCompany Announcements
Processa Pharmaceuticals Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 2 trial for NGC-Cap is designed to evaluate the safety-efficacy profile of NGC-Cap versus monotherapy capecitabine, which could lead to positive advancements in treating advanced or metastatic breast cancer.
Drug DevelopmentPCS6422 is found to be more than 50 times more potent than currently marketed capecitabine, as measured by 5-FU systemic exposure.
Bears Say
Financial StabilityThe cash balance is not believed to be sufficient to complete the Phase 2 trial, posing a risk of delays for the interim analysis.
Market PerformanceThe stock is trading near a 52-week low, reflecting market cap challenges.
Options Prices
Currently, No data available
---
Ownership Overview
5.86% Insiders
0.39% Mutual Funds
0.92% Other Institutional Investors
92.63% Public Companies and Individual Investors
PCSA FAQ
What was Processa Pharmaceuticals’s price range in the past 12 months?
Processa Pharmaceuticals lowest stock price was $0.15 and its highest was $3.10 in the past 12 months.
What is Processa Pharmaceuticals’s market cap?
Processa Pharmaceuticals’s market cap is $3.43M.
When is Processa Pharmaceuticals’s upcoming earnings report date?
Processa Pharmaceuticals’s upcoming earnings report date is Aug 07, 2025 which is in 61 days.
How were Processa Pharmaceuticals’s earnings last quarter?
Processa Pharmaceuticals released its earnings results on Mar 27, 2025. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.845 by $0.075.
Is Processa Pharmaceuticals overvalued?
According to Wall Street analysts Processa Pharmaceuticals’s price is currently Undervalued.
Does Processa Pharmaceuticals pay dividends?
Processa Pharmaceuticals does not currently pay dividends.
What is Processa Pharmaceuticals’s EPS estimate?
Processa Pharmaceuticals’s EPS estimate is -0.21.
How many shares outstanding does Processa Pharmaceuticals have?
Processa Pharmaceuticals has 11,884,356 shares outstanding.
What happened to Processa Pharmaceuticals’s price movement after its last earnings report?
Processa Pharmaceuticals reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.845. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Processa Pharmaceuticals?
Currently, no hedge funds are holding shares in PCSA
Company Description
Processa Pharmaceuticals
Processa Pharmaceuticals (PCSA) is a clinical-stage biopharmaceutical company focused on developing innovative drug products to address unmet medical needs. Operating primarily in the biopharmaceutical and healthcare sectors, the company is committed to advancing its pipeline of promising drug candidates through various stages of clinical development to ultimately improve patient outcomes.
PCSA Stock 12 Month Forecast
Average Price Target
$6.00
▲(1968.97%Upside)